Franklin Resources Inc. Has $29.64 Million Position in HilleVax, Inc. (NASDAQ:HLVX)

Franklin Resources Inc. increased its position in HilleVax, Inc. (NASDAQ:HLVXFree Report) by 4.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,846,396 shares of the company’s stock after purchasing an additional 71,938 shares during the quarter. Franklin Resources Inc. owned approximately 3.81% of HilleVax worth $29,635,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in HLVX. Swiss National Bank raised its position in shares of HilleVax by 22.4% during the 4th quarter. Swiss National Bank now owns 38,200 shares of the company’s stock valued at $613,000 after acquiring an additional 7,000 shares during the last quarter. abrdn plc bought a new stake in HilleVax in the fourth quarter valued at about $433,000. SG Americas Securities LLC acquired a new position in HilleVax in the fourth quarter valued at about $139,000. Acuta Capital Partners LLC lifted its stake in HilleVax by 328.5% in the third quarter. Acuta Capital Partners LLC now owns 270,319 shares of the company’s stock valued at $3,636,000 after buying an additional 207,241 shares during the period. Finally, Adage Capital Partners GP L.L.C. bought a new position in HilleVax during the third quarter worth about $2,374,000. 86.42% of the stock is owned by institutional investors.

HilleVax Trading Down 1.5 %

HilleVax stock opened at $12.89 on Monday. HilleVax, Inc. has a twelve month low of $9.94 and a twelve month high of $20.22. The company has a current ratio of 10.92, a quick ratio of 10.92 and a debt-to-equity ratio of 0.11. The company has a 50 day moving average of $14.38 and a 200-day moving average of $14.98.

HilleVax (NASDAQ:HLVXGet Free Report) last announced its earnings results on Wednesday, March 20th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.02. Equities analysts predict that HilleVax, Inc. will post -3.14 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HLVX shares. JPMorgan Chase & Co. upped their price target on HilleVax from $21.00 to $24.00 and gave the company an “overweight” rating in a research note on Wednesday, May 15th. HC Wainwright reaffirmed a “buy” rating and issued a $28.00 target price on shares of HilleVax in a research note on Friday, May 10th.

Get Our Latest Report on HLVX

Insider Transactions at HilleVax

In other news, major shareholder Life Sciences X. L.P. Frazier bought 8,850 shares of the business’s stock in a transaction on Thursday, April 4th. The shares were purchased at an average price of $14.50 per share, for a total transaction of $128,325.00. Following the purchase, the insider now owns 8,544,187 shares of the company’s stock, valued at approximately $123,890,711.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. In other news, Director Aditya Kohli sold 6,000 shares of the stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $18.66, for a total transaction of $111,960.00. Following the completion of the transaction, the director now directly owns 825,776 shares in the company, valued at approximately $15,408,980.16. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Life Sciences X. L.P. Frazier acquired 8,850 shares of the firm’s stock in a transaction dated Thursday, April 4th. The stock was bought at an average price of $14.50 per share, with a total value of $128,325.00. Following the acquisition, the insider now directly owns 8,544,187 shares in the company, valued at $123,890,711.50. The disclosure for this purchase can be found here. Insiders sold 48,898 shares of company stock valued at $986,027,606 over the last three months. Company insiders own 71.10% of the company’s stock.

HilleVax Profile

(Free Report)

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.

See Also

Institutional Ownership by Quarter for HilleVax (NASDAQ:HLVX)

Receive News & Ratings for HilleVax Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HilleVax and related companies with MarketBeat.com's FREE daily email newsletter.